Title: Right Ventricular Dysfunction in Ventilated Patients with COVID-19 (COVID-RV).

Dr Philip McCall^{1,2}, Dr Jennifer Willder³, Miss Bethany Stanley⁴, Dr Claudia-Martina Messow⁴, Dr John Allan⁵, Dr Lisa Gemmell⁶, Dr Alex Puxty⁷, Dr Dominic Strachan⁸, Professor Colin Berry⁹, Dr Ben Shelley^{1,2}, The COVID-RV investigators.

1. Anaesthesia, Critical Care & Peri-operative Medicine Research Group, University of Glasgow, UK.
2. Department of Anaesthesia, Golden Jubilee National Hospital, Clydebank, UK.
3. West of Scotland School of Anaesthesia, NHS Education for Scotland, Glasgow, UK.
4. Robertson Centre for Biostatistics, University of Glasgow, UK
5. Intensive Care Unit, University Hospital Crosshouse, Kilmarnock, UK.
6. Intensive Care Unit, Royal Alexandra Hospital, Paisley, UK.
7. Intensive Care Unit, Glasgow Royal Infirmary, UK.
8. Intensive Care Unit, University Hospital Wishaw, Wishaw, UK.
9. Institute of Cardiovascular and Medical Sciences, University of Glasgow, UK.

Corresponding author: Dr Philip McCall
philip.mccall@glasgow.ac.uk
 ORCID ID: 0000-0001-5828-3371

ClinicalTrials.gov Identifier: NCT04764032 (Registered 21st Feb 2021)

Keywords: Right Ventricle, COVID-19, Echocardiography, ARDS

Declarations

Funding

This work was supported by Medical Research Scotland (grant number CVG-1730-2020). BSh is supported by the National Institute of Academic Anaesthesia / Royal College of Anaesthetists British Oxygen Company Chair of Anaesthesia Research Grant. Colin Berry receives research funding from the British Heart Foundation grant (RE/18/6134217), Chief Scientist Office, EPSRC (EP/R511705/1, EP/S030875/1), European Union (754946-2), Medical Research Council (MR/S018905/1) and UKRI (MC/PC/20014).

Conflicts of interest/Competing interests (include appropriate disclosures)

Colin Berry is employed by the University of Glasgow which holds consultancy and research agreements for his work with Abbott Vascular, AstraZeneca, Boehringer Ingelheim, Causeway Therapeutics, Coroventis, Genentech, GSK, HeartFlow, Menarini, Neovasc, Siemens Healthcare, and Valo Health.

Authors' contributions

BSh and PM conceived the study and BSh is the grant holder. PM, JW, CB and BSh contributed to study design and funding application. JW wrote the patient documentation and developed the case report forms and online data collection database. JA, LG, AP and DS led patient recruitment. BSt and C-MM performed the statistical analyses. All authors contributed to the manuscript and approved the final document.

Ethics approval: Approval was gained from Scotland A Research Ethics Committee (REC reference 20/SS/0059).

Consent to participate

Informed consent was obtained from all participants included in the study, or their legal representative.

Take-home message

In a prospective cohort of 121 patients with COVID-19 requiring mechanical ventilation, echocardiographic evidence of right ventricular dysfunction was present in 6.2% and was associated with high mortality. There was association between right ventricular dysfunction and acute respiratory distress syndrome, mechanical ventilation, pulmonary thromboembolism and myocardial injury.

Tweet

COVID-RV demonstrates #EchoFirst evidence of #RightVentricle dysfunction in ventilated #COVID-19 patients
 with ARDS. No implications on research that has not been certified by peer review and should not be used to guide clinical practice.

COVID-RV investigators

A Reece, C Kitchen, M Gillies, V. Dabek, V. Irvine, COVID-RV trial management group; J MacBrayne, K Sim, T Scott, E Trumper, F Savage, A Allan, J Falconer and A Coutts, Aberdeen Royal Infirmary; A McDonald, J Rutherford, D Christie and C Jardine, Dumfries & Galloway Royal Infirmary; M Hughes and S Cathcart, Glasgow Royal Infirmary; M Sim, B Docking and M Thornton, Queen Elizabeth University Hospital, Glasgow; B Gatrex, J Rae, C Barr, C Bradley, F Barrett, R Campbell, N Clarke, M Mascarenhas, J Matheson, D McDonald, M O'Hara and L O'keeffe, Raigmore Hospital, Inverness; R Price and M McHendry, Royal Alexandra Hospital, Paisley; D McLaughlan, C Herman, H Elliot and S Meehan, University Hospital Ayr; D Finn, G Brannan, S Wood, T Watson and K Ross, University Hospital Crosshouse; N Tatarkowska, R Boyle and E Lee, University Hospital Hairmyres; A Morrison, P Lucie, C Lochrin, S Clements and D Vigni, University Hospital Wishaw

ABSTRACT

Purpose

COVID-19 is associated with cardiovascular complications, with right ventricular dysfunction (RVD) commonly reported. The combination of acute respiratory distress syndrome (ARDS), injurious invasive ventilation, micro/macro thrombi and the potential for direct myocardial injury create conditions where RVD is likely to occur. No study has prospectively explored the prevalence of RVD, and its association with mortality, in a cohort requiring mechanical ventilation.

Methods

Prospective, multi-centre, trans-thoracic echocardiographic, cohort study of ventilated patients with COVID-19 in Scottish intensive care units. RVD was defined as the presence of severe RV dilatation and interventricular septal flattening. To explore role of myocardial injury, high sensitivity troponin and N-terminal pro B-type natriuretic peptide (NT-proBNP) were measured in all patients.

Results

One hundred and twenty-one patients were recruited to COVID-RV, 118 underwent imaging and it was possible to determine the primary outcome in 112. RVD was present in seven (6.2% [95%CI; 2.5%, 12.5%]) patients. Thirty-day mortality was 85.7% in those with RVD, compared to 44.8% in those without ($p=0.051$). Patients with RVD were more likely to have; pulmonary thromboembolism ($p<0.001$), higher plateau pressure ($p=0.048$), lower dynamic compliance ($p=0.031$), higher NT-proBNP ($p<0.006$) and more frequent *abnormal* troponin ($p=0.048$). Abnormal NT-proBNP (OR 4.77 [1.22, 21.32], $p=0.03$) and abnormal Troponin (16.54 [4.98, 67.12], $p<0.001$) independently predicted 30-day mortality.

Conclusion

COVID-RV demonstrates a prevalence of RVD in ventilated patients with COVID-19 of 6.2% and is associated with a mortality of 85.7%. Association is observed between RVD and each of the aetiological domains of; ARDS, ventilation, micro/macro thrombi and myocardial injury.

INTRODUCTION

Since March 2020 there has been a global pandemic of Coronavirus disease 2019 (COVID-19), caused by the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). COVID-19 can result in acute hypoxaemic respiratory failure which in severe cases may require admission to intensive care (ICU) and invasive mechanical ventilation. Haemodynamic instability and cardiac complications are prevalent, with right ventricular dysfunction (RVD) a common finding [1-10]. The combination of acute respiratory distress syndrome (ARDS), injurious invasive ventilation, micro/macro thrombi and the potential for direct myocardial injury create a *perfect storm* of pathophysiology where RVD is likely to occur [11]. In reports pre-dating the COVID-19 pandemic, RVD occurs in up to 55% of patients with ARDS and is independently associated with mortality, with increasing ARDS severity associated with increased frequency of RV dysfunction [12,13].

Previous echocardiography studies in COVID-19 have demonstrated RVD and association with adverse clinical outcomes [1,3-10]. To date however, most of the research into RVD in COVID-19 has been retrospective and performed in undifferentiated cohorts, *of ventilated and non-ventilated patients* [3-6,8-10]. As highlighted by Michard and Vieillard-Baron in February's issue of *Intensive Care Medicine*, to date, there have been no robust, *prospective*, haemodynamic evaluations of patients with COVID-19 focusing *specifically on the intensive care unit population* [2]. To this end, COVID-RV was designed to prospectively investigate the prevalence of RV dysfunction in ventilated patients with COVID-19, any association with mortality and, to explore causative mechanisms.

METHODS

Study design and participants

Study protocol and methods have previously been reported [14]. We conducted a prospective, observational cohort study involving 10 ICUs in NHS Scotland. Ethics approval was obtained from Scotland A Research Ethics Committee (responsible for studies requiring approval under the Adults with Incapacity [Scotland] Act, 2000 - 20/SS/0059). Patients were eligible for inclusion if they were more than 16 years old with confirmed SARS-CoV-2 infection, with severe acute respiratory failure requiring tracheal intubation and positive pressure ventilation in ICU for more than 48 hours, but not more than 14 days. Exclusion criteria were; pregnancy, ongoing participation in investigational research that may undermine the scientific basis of the study, prior participation in COVID-RV, requirement for extracorporeal membrane oxygenation support (for respiratory or cardiovascular failure) and end of life care where the patient was not expected to survive longer than 24 hours. COVID-RV was registered at ClinicalTrials.gov (NCT04764032).

Data

Study data were collected and managed using REDCap electronic data capture tools hosted by the University of Glasgow.

Clinical and laboratory data

Baseline demographics, chronic comorbidities, clinical trajectory prior to ICU admission, severity of illness, acute comorbidities and follow-up data were all collected prospectively. Clinical data relating to potential mechanisms of RV dysfunction were also collected, specifically regarding the four domains of; ARDS, disordered coagulation, myocardial injury and mechanical ventilation.

Echocardiography

Participants underwent a single transthoracic echocardiogram (TTE) to determine the presence or absence of RV dysfunction. To reflect the clinical practice of bedside echocardiography in intensive care, for the purposes of determining the primary outcome of the study, imaging required was in keeping with the protocol required for a focused intensive care echo (FICE) scan [15]. In line with previous reports, RVD was defined as TTE evidence of severe RV dilatation along with the presence of interventricular septal flattening. Severe RV dilatation was determined from the apical 4-chamber view at end diastole and was present when the RV:left ventricular (LV) ratio was >1 .

Cardiac biomarkers

High sensitivity troponin (I or T depending on assay used at each site) and N-terminal pro B-type natriuretic peptide (NT-proBNP) were measured in all patients on the day of echocardiography. Samples were processed alongside routine clinical samples in each host site, and therefore subject to routine laboratory quality assurance processes. Abnormal values were defined for NT-proBNP ($>300\text{ng/ml}$) and Troponin ($\text{TnT} \geq 15\text{ ng/L}$ or $\text{TnI} \geq 34\text{ ng/L}$ for males; $\geq 16\text{ ng/L}$ for females).

Statistical considerations

Statistical analyses were performed by statisticians (B.S., C.-M.M.) based in the Robertson Centre for Biostatistics at the University of Glasgow.

Outcomes

The primary outcome was the prevalence of RV dysfunction and its association with 30-day mortality. Exploratory outcomes sought to determine association between RVD and proposed aetiological factors. Additionally, association between cardiac biomarker levels and 30-day mortality was assessed.

Power

Sample size selection was, by necessity, a pragmatic balance of maximising available information versus the prompt delivery of the study. Given the number of patients admitted to ICU in Scotland during the first wave of the pandemic (Q2, 2020), we believed it was realistic to recruit 120–150 patients across participating sites. Power calculations were performed for estimated RV dysfunction prevalence rates of 25% and 50%, with an overall mortality rate of 50% and are demonstrated in supplementary table 1. These analyses suggest that a study of 120 patients (the ultimate sample size) would have 80% power to detect an associated odds ratio (OR) for mortality of 2.83 to 3.43 (with an estimated prevalence of RVD of 50% and 25% respectively).

Statistical methods

The proportion of ventilated patients with COVID-19 who have RVD was determined, with a 95% confidence interval (CI) utilising the Clopper-Pearson method. We then sought to analyse the association of RV dysfunction with 30-day mortality using logistic regression analysis predicting 30-day mortality from presence or absence of RV dysfunction, adjusting for patient demographics (age, gender, ethnicity), phase of disease (time from intubation to echocardiography) and baseline severity of illness (Acute Physiology And Chronic Health

Evaluation II [APACHE II] score). Firth's bias-reduced logistic regression was used where ordinary logistic regression failed due to small numbers [16]. Association of the cardiac biomarkers with 30-day mortality was assessed using logistic regression analysis, predicting 30-day mortality and adjusted for patient demographics, phase of disease and baseline severity of illness. Ordinal and categorical data are presented as n (%). Continuous data are summarised as mean (standard deviation [SD]) or median (interquartile range [IQR]) as appropriate. Between-group differences were assessed using Fisher's Exact test for categorical variables and Student's T- or Wilcoxon Mann-Whitney test for continuous variables. Statistical analyses were performed using R version 4.0.0 (R Foundation for Statistical Computing, Vienna, Austria).

RESULTS

Between 2nd September 2020 and 22nd March 2021, 121 patients were recruited to COVID-RV (Figure 1). Following recruitment, three patients were excluded from further participation; one who was extubated prior to echocardiography and two as a result of technical factors preventing imaging. Patient characteristics at ICU admission are provided in table 1. Thirty-day mortality in the whole cohort was 47.3% (53 of 112 died).

Of the 118 patients where TTE was performed, it was possible to determine the primary outcome in 112 (94.9%, supplementary table 1). Echocardiography was performed by; British Society of Echocardiography accredited echocardiographers (n=55 [46.6%]), FICE accredited critical care clinicians with “mentor” status (n=37 [31.4%]), FICE accredited clinicians (n=8 [6.8%]) and clinicians without any formal accreditation (n=18 [15.3%]). Imaging was performed a median of 5 (4, 8) days following intubation. Thirty-one (27.7%) patients had evidence of severe RV dilatation (RV:LV ratio >1:1 on A4C view) and nine (8%) had evidence of interventricular septal flattening. Right ventricular dysfunction (the combination of these two parameters and primary endpoint) was present in seven (6.2% [95% CI; 2.5%, 12.5%]) patients (Figure 2). *Subjective* RV dysfunction was present in 85.7% of those with RVD, in contrast to 9.6% in those without (p<0.001). *Subjective* LV dysfunction was present in 28.6% of those with RVD, in contrast to 9.7% in those without (p=0.168, table 2). There was no difference in time from *intubation* to imaging in those with or without RVD (p=0.942); time from *symptom onset* to echocardiography however was longer in those with RVD compared to those without (23 [20, 29.5] days compared to 17 [13, 21.2] days, p=0.017, table 2).

Patients with RVD had a higher creatinine at the time of imaging and were more likely to be undergoing RRT (p=0.014 and 0.049 respectively, table 5). Heart rate was higher in patients with RVD (p=0.016) and they had more disordered acid-base status (p≤0.001, table 5).

Association with mortality

Six of seven patients (85.7%) with RVD were deceased by the time of 30-day follow up compared to 47 of 105 (44.8%) without RVD (p=0.051, table 3). Firth’s bias-reduced regression analyses demonstrated the presence of RVD was not a significant predictor of 30-day mortality (OR [95%CI] 5.12 [0.99, 51.38], p=0.051, table 4).

Association with aetiological factors

Disordered coagulation

Radiologically confirmed or clinically suspected pulmonary thromboembolism (PTE), was present in 57.1% of patients with RVD, compared to 4.8% in those without ($p<0.001$, table 1). In keeping with this, treatment with anticoagulation was more common in those with RVD ($p=0.018$, table 5). There was no difference in platelets, prothrombin time, activated prothrombin time, and D-Dimer between the two groups ($p>0.120$, table 5).

Mechanical ventilation

Where it could be measured, plateau pressure was higher, and compliance lower, in the population with RVD ($p=0.048$ and 0.031 respectively, table 5). There was no difference in, peak airway pressure, positive end expiratory pressure, driving pressure, or indexed tidal volume between groups ($p>0.086$ for all, table 5).

Severity of ARDS

There was no difference in the $\text{PaO}_2/\text{FiO}_2$ (PF) ratio, requirement for prone ventilation in the previous 24 hours or Murray lung injury score [17] between groups ($p>0.36$ for all, table 5).

Myocardial Injury

There was no difference in the *proportion* of patients with normal or abnormal NT-proBNP levels, between those with and without RVD ($p=0.255$). However, *median* NT-proBNP values were higher in those *with* RVD ($p<0.006$, table 5 and Figure 3). Conversely, there was no difference in *median* Troponin levels (I or T) between the groups ($p>0.082$). However, abnormal Troponin values were more frequent in those *with* RVD ($p=0.048$, table 5).

Regression analyses controlling for demographics, phase of disease and baseline severity of illness demonstrated; an abnormal NT-proBNP (OR [95%CI] 4.77 [1.22, 21.32], $p=0.029$), and an abnormal Troponin (16.54 [4.98, 67.12], $p<0.001$) both independently predicted 30-day mortality (Table 6).

Post-hoc analyses

Post-hoc analyses examining the alternative endpoint of RVD as defined by the presence of RV dilatation *and/or* septal flattening are presented as Supplementary tables. This endpoint occurred in 33 of 112 patients, 29.5% [95% CI; 21.2%, 38.8%], figure 1) but was not associated with mortality (51.5% in those with, compared to 45.6% in those without, $p=0.679$, supplementary table 4.). Regression analyses, controlling for patient demographics, phase

of disease and baseline severity of illness demonstrated no association between this definition of RVD and 30-day mortality (Supplementary Table 6).

DISCUSSION

To our knowledge, this is the first study to prospectively explore the prevalence of RV dysfunction in *ventilated patients* with COVID-19. The prevalence of RVD was 6.3% and this was associated with a mortality of 85.7%, in contrast to 44.8% in those without RVD.

A universal definition of *right ventricular dysfunction* is not well established; it has been suggested the term refers to structural changes (abnormal imaging and/or biomarkers) but with maintained cardiac output, a clinical setting which may progress to *right ventricular failure* (RVF). RVF is characterised by insufficient delivery of blood from the RV along with elevated systemic venous pressures [18]. As RVF is a difficult *clinical* diagnosis to make, we elected to refer to the echocardiographic changes as RVD. There is however, a high likelihood that patients in COVID-RV with a diagnosis of RVD would also have fitted clinical criteria for RVF, where there was associated evidence of tachycardia, systemic hypoperfusion (disordered acid-base status) and renal dysfunction.

Echocardiographic assessment of RV function is challenging; due to its complex geometry, retrosternal position, and marked load dependence. As a result, there is no gold-standard numeric measurement of RV function and international guidelines advocate assessment should incorporate a combination of both qualitative and quantitative parameters [19]. These quantitative methods however have been observed to vary markedly in their diagnostic performance [20]. More importantly, for COVID-RV, they are not assessed as part of a focused, bedside FICE echocardiogram. We deliberately selected a pragmatic definition of RVD, so as to empower bedside critical care clinicians, to make the diagnosis [21]. Identification of RVD could inform patient prognosis, alert to the potential for associated pathologies, such as PTE, and influence treatment strategies; such as alteration of ventilation, introduction of inotropic support or pulmonary vasodilators. Furthermore, should any interventional study of RV therapies be proposed in this patient group, it is imperative that any inclusion criteria (i.e., the diagnosis of RVD) allows the treating bedside clinician to make the diagnosis.

RV dilatation and septal flattening together constitute *acute cor pulmonale* (ACP). This has been more specifically defined as septal flattening with a dilated RV (RV:LV ratio >0.6, with >1.0 for *severe* ACP) [22]. The observed prevalence of RVD (defined as *severe* RV dilation *and* septal flattening) at 6.3% was lower than hypothesised. In the early phases of the pandemic, anecdotal clinical reports, social media posts and early peer reviewed literature suggested RVD was very common; RV dilatation was reported to be present in 31-39% of cases [1,3,4,23]. These

studies however had mechanical ventilation rates of only 10-30% and therefore it was hypothesised the prevalence of RVD would be higher in a cohort requiring intubation and mechanical ventilation; previous reports of RVD in ARDS described a prevalence of up to 50% [13,24]. This lesser prevalence may have been observed for a number of reasons: Firstly, these early anecdotal, observational and retrospective reports are likely to have been influenced by selection bias, where only patients who were haemodynamically unstable or deteriorating would have imaging performed, meaning the prevalence of RVD was over reported. COVID-RV recruited 23.9% of all patients admitted to participating ICU's during the study period; the prospective and systematic approach to patient recruitment, provides confidence that the prevalence of RVD presented is accurate. When compared to contemporaneous national reporting by both the Intensive Care National Audit & Research Centre (ICNARC) and the Scottish Intensive Care Society Audit Group (SICSAG), the patients recruited to COVID-RV are representative in terms of severity of illness, and mortality [25,26]. Secondly, there were significant differences in patient demographics, clinical care and outcomes between the time of these early reports and the UK's "second wave" when the COVID-RV cohort was recruited. Attitudes to non-invasive respiratory support, ventilation practice, fluid management and anticoagulation all evolved and successful drug therapies were discovered and implemented; 66.1% of COVID-RV participants were treated with intravenous steroids prior to intubation [27,28]. Thirdly, the definition of RVD used in this study, necessitating the presence of both *severe* RV dilatation *and* septal flattening is a more stringent definition than used in other reports. The alternative endpoint of RV dilatation *and/or* septal flattening was evident in 29.5% of patients (Supplemental tables 3-6) whilst *subjective* RV *dysfunction* was diagnosed in 14.4%.

Our findings however, are in keeping with previous reports in ARDS. In a study of 752 patients by Mekontso Dessap et al. ACP was present in 22% (95% CI 19, 25%) and *severe* ACP (the same definition as used in COVID-RV) was present in 7.2% (95% CI 5.4%, 9.3%) [13]. Importantly, in this study, as in COVID-RV, hospital mortality was only higher in patients with *severe* ACP when compared with all other patients (57% compared to 42% in those without [p=0.03]), suggesting this definition of RVD identifies a population of patients where diagnosis yields significant clinical sequelae.

High driving pressure, low P/F ratio and high PaCO₂ have been associated with RVD in patients with ARDS [13]. Although COVID-RV was not able reproduce these findings, the study demonstrated that plateau pressure was

higher, and compliance lower, in those with RVD suggesting interplay between ARDS and the conduct of mechanical ventilation in the aetiology of RVD in this population.

The observed association between *confirmed or suspected* PTE and RVD is not un-expected and demonstrates the role of macrothrombi in RVD. It has been consistently demonstrated that patients with COVID-19 in ICU have a high frequency of thrombotic complications with a PTE incidence of 12.6% [29]. RVD is common in patients with PTE and is a major determinant of short-term survival [30,31].

Cardiomyocyte injury, quantified by elevated troponin levels, and haemodynamic cardiac stress, as quantified by increased natriuretic peptide concentrations have been previously described both in COVID-19 and ARDS [32-34]. The association of NT-proBNP and abnormal troponin levels with RVD in this cohort suggests a potential role of direct myocardial injury in the aetiology of myocardial dysfunction in patients with COVID-19. Our findings are consistent with previous work, with elevation of NT-proBNP and troponin strongly associated with mortality.

The lack of association between time from *intubation to echocardiography* and RVD suggests the phase of a patient's *ICU* stay does not influence the presence of RVD. The timing of intubation however is multi-factorial, varying from patient to patient and ICU to ICU; some patients for example will be intubated late, following prolonged periods of non-invasive respiratory support, and others will have been intubated much earlier. However, the observed association between *time of symptom onset to echocardiography* and RVD, suggests the overall stage of a patient's disease process may influence the presence of RVD. Previous work has demonstrated higher incidences of VTE with increasing time since COVID-19 diagnosis and given the association between PTE and RVD, this may contribute to this finding in the COVID-RV cohort [35].

Strengths of this study include a prospective, a-priori analysis of RVD in a cohort requiring mechanical ventilation using a well-established definition, known to be associated with outcome in patients with ARDS. A weakness of the study is the single timepoint of echocardiographic assessment, it is unknown whether patients classified as not having RVD may have had abnormal echocardiography if imaging had occurred at a different timepoint during their admission. Although an accurate report of the prevalence of RVD in ventilated patients with COVID-19, the low numbers of the primary outcome event prevent any in depth multi-variate assessment of the factors associated

with RVD. In addition, the associations demonstrated are at risk of both type I and type II error, meaning they can only be considered exploratory in nature.

COVID-RV demonstrates that although the prevalence of RVD is lower than predicted in ventilated patients with COVID-19, it is associated with a high mortality. Association is observed between RVD and each of the aetiological domains of; ARDS, ventilation, micro/macrothrombi and myocardial injury. COVID-RV highlights the need for increased clinician awareness of RVD and should aid design of therapeutic studies seeking to improve outcome in this critically ill patient group.

TABLES

Table 1. Patient characteristics at ICU admission					
		All (n=112)	RVD (n=7)	No RVD (n=105)	p-value
Age, years		59.2 (11.3)	61.1 (4.4)	59 (11.6)	0.318 [#]
Male		74 (66.1%)	5 (71.4%)	69 (65.7%)	>0.99 [†]
BMI, kg/m2	<i>n (n missing)</i>	110 (2)	7 (0)	103 (2)	
		32.9 (7.1)	31.5 (4.6)	32.9 (7.2)	0.467 [#]
Ethnicity	White	100 (89.3%)	7 (100%)	93 (88.6%)	
	Non-white	12 (10.7%)	0 (0%)	1 (1%)	>0.99 [†]
Time since symptom onset to intubation, days		11 [7, 16]	18 [13, 25]	10.5 [7, 14.2]	0.035 [‡]
Clinical frailty score	<i>n (n missing)</i>	111 (1)	7 (0)	104 (1)	
		2.4 (0.9)	2 (0.8)	2.4 (0.9)	0.281 [#]
APACHE II	<i>n (n missing)</i>	107 (5)	7 (0)	100 (5)	
		16.6 (5.8)	17.6 (6.1)	16.6 (5.8)	0.687 [#]
CCCC	<i>n (n missing)</i>	102 (10)	7 (0)	95 (10)	
		10.2 (2.7)	10.6 (2.3)	10.2 (2.8)	0.712 [#]
Comorbidities					
Smoking	Non-smoker	63 (56.2%)	2 (28.6%)	61 (58.1%)	
	Ex-smoker > 1 year	40 (35.7%)	4 (57.1%)	36 (34.3%)	=0.228 [†]
	Current or within 1 year	9 (8%)	1 (14.3%)	8 (7.6%)	
Alcohol history	<i>n (n missing)</i>	110 (2)	7 (0)	103 (2)	
	None	34 (30.9%)	1 (14.3%)	33 (32%)	
	Minimal	57 (51.8%)	6 (85.7%)	51 (49.5%)	=0.478 [†]
	Moderate	8 (7.3%)	0 (0%)	8 (7.8%)	
	Excess	11 (10%)	0 (0%)	11 (10.7%)	
Hypertension		38 (33.9%)	2 (28.6%)	36 (34.3%)	>0.99 [†]
Coronary artery disease		11 (9.8%)	0 (0%)	11 (10.5%)	>0.99 [†]
Diabetes		33 (29.5%)	2 (28.6%)	31 (29.5%)	>0.99 [†]
Asthma		16 (14.3%)	1 (14.3%)	15 (14.3%)	>0.99 [†]
COPD		10 (8.9%)	0 (0%)	10 (9.5%)	>0.99 [†]
Treatments before intubation					
Intravenous corticosteroids		74 (66.1%)	4 (57.1%)	70 (66.7%)	0.687 [†]
Non-invasive ventilation		76 (67.9%)	6 (85.7%)	70 (66.7%)	0.426 [†]
High flow nasal oxygen		65 (58%)	6 (85.7%)	59 (56.2%)	0.235 [†]
Awake self-proning		57 (50.9%)	6 (85.7%)	51 (48.6%)	0.114 [†]
Acute comorbidities since hospital admission					
New arrhythmias		17 (15.2%)	3 (42.9%)	14 (13.3%)	0.070 [†]
Confirmed or suspected PTE	Radiologically confirmed	4 (3.6%)	3 (42.9%)	1 (1%)	
	Clinically suspected	5 (4.5%)	1 (14.3%)	4 (3.8%)	
	No	101 (90.2%)	3 (42.9%)	98 (93.3%)	<0.001 [†]
	Unknown	2 (1.8%)	0 (0%)	2 (1.9%)	
ACS		5 (4.5%)	0 (0%)	5 (4.8%)	>0.99 [†]
Requirement for RRT		18 (16.1%)	2 (28.6%)	16 (15.2%)	0.313 [‡]

Data are presented as mean (SD), median [IQR] or n (%). Data are complete unless indicated by *n (n missing)*. P-values provided are for comparisons between RVD vs no RVD. # = Student's T-test. † = Fisher's Exact test. ‡ = Wilcoxon Mann-Whitney test.

RVD = Right Ventricular Dysfunction, BMI = Body Mass Index, APACHE = Acute Physiology And Chronic Health Evaluation, CCCC = Coronavirus Clinical Characterisation Consortium, COPD = Chronic Obstructive Pulmonary Disease, PTE = Pulmonary Thromboembolism, ACS = Acute Coronary Syndrome, RRT = Renal Replacement Therapy.

Table 2. Echocardiography

		All (n=112)	RVD (n=7)	No RVD (n=105)	p-value
Time from symptom onset to echocardiography, days	<i>n (n missing)</i>	111 (1) 18 [13, 22]	7 (0) 23 [20, 29.5]	104 (1) 17 [13, 21.2]	0.017 [‡]
Time from intubation to echocardiography, days		5 [4, 8]	5 [5, 6]	5 [4, 8]	0.942 [‡]
RV dilatation	<i>n (n missing)</i>	110 (2) 31 (27.7%)	7 (0) 7 (100%)	103 (2) 24 (22.9%)	-
Septal flattening	<i>n (n missing)</i>	109 (3) 9 (8%)	7 (0) 7 (100%)	102 (3) 2 (1.9%)	-
Subjective LV dysfunction	<i>n (n missing)</i>	110 (2) 12 (10.9%)	7 (0) 2 (28.6%)	103 (2) 10 (9.7%)	0.168 [†]
Subjective RV dysfunction	<i>n (n missing)</i>	111 (1) 16 (14.4%)	7 (0) 6 (85.7%)	104 (1) 10 (9.6%)	<0.001 [†]

Data are presented as median [IQR] or n (%). Data are complete unless indicated by *n (n missing)*. P-values provided are for comparisons between RVD vs no RVD. [‡] = Wilcoxon Mann-Whitney test. [†] = Fisher's Exact test.
RV = Right Ventricular, LV = Left Ventricular.

Table 3. Clinical consequences				
	All (n=112)	RVD (n=7)	No RVD (n=105)	p-value
<i>30-day follow-up</i>				
Death	53 (47.3%)	6 (85.7%)	47 (44.8%)	0.051 [†]
RRT	28 (25%)	3 (42.9%)	25 (23.8%)	0.581 [†]
Prone ventilation	55 (49.1%)	2 (28.6%)	53 (50.5%)	0.322 [†]
Referral for ECMO	15 (13.4%)	0 (0.0%)	15 (14.3%)	0.663 [†]
Data are presented as n (%). Data are complete unless indicated by <i>n</i> (<i>n missing</i>). P-values provided are for comparisons between RVD vs no RVD. † = Fisher's Exact test.				
RRT = Renal Replacement Therapy, ECMO = Extra Corporeal Membrane Oxygenation.				

Table 4. Firth's bias reduced logistic regression predicting 30-day mortality adjusting for remaining variables in table

	OR (95% CI)	p-value
RVD (RV dilatation and septal flattening)	5.12 (0.99, 51.38)	=0.051
Age, in years (per 5-year increase)	1.48 (1.19, 1.91)	<0.001
Female Gender	1.12 (0.46, 2.73)	=0.803
Non-white ethnicity	0.92 (0.22, 3.54)	=0.899
APACHE II score on admission to ICU (per 5-score increase)	1.27 (0.87, 1.90)	=0.221
Time from intubation to date of echo, in days (per 1-day increase)	1.01 (0.88, 1.17)	=0.837
RVD = Right Ventricular Dysfunction, APACHE = Acute Physiology And Chronic Health Evaluation		

Table 5. Patient characteristics on day of echocardiography

		All (n=112)	RVD (n=7)	No RVD (n=105)	p-value
Requirement for prone invasive ventilation since ICU admission		79 (70.5%)	7 (100%)	72 (68.6%)	0.240 [†]
SOFA score		7.9 (3)	9.3 (4.2)	7.8 (2.9)	0.408 [#]
Requirement for RRT on day of echo		15 (13.4%)	3 (42.9%)	12 (11.4%)	0.049 [†]
Lab Measurements					
Arterial Blood Gas					
[H⁺], nmol/L)	<i>n (n missing)</i>	97 (15) 39 [35.8, 46]	5 (2) 53 [53, 60.9]	92 (13) 38.5 [35, 45]	=0.001 [‡]
PaO₂, kPa		9.3 (1.2)	8.8 (1)	9.3 (1.3)	0.219 [#]
PaCO₂, kPa	<i>n (n missing)</i>	109 (3) 6.9 [5.9, 8]	7 (0) 7.6 [6.2, 8.8]	102 (3) 6.8 [5.9, 7.9]	0.390 [‡]
BE, mmol	<i>n (n missing)</i>	110 (2) 5.9 (6.5)	7 (0) -1.2 (3.2)	103 (2) 6.4 (6.4)	<0.001 [#]
Bicarbonate, mmol/L	<i>n (n missing)</i>	109 (3) 31.8 (6.6)	7 (0) 26.2 (2.7)	102 (3) 32.1 (6.6)	<0.001 [#]
Full Blood Count					
Haemoglobin, g/dl		11 (1.8)	10.1 (1.2)	11.1 (1.8)	0.073 [#]
Neutrophils, x10⁹/L		10.5 [8.5, 14.9]	9.8 [8.4, 13.3]	10.5 [8.5, 14.6]	0.512 [‡]
Lymphocytes, x10⁹/L		0.9 [0.5, 1.4]	1 [0.9, 1.9]	0.9 [0.5, 1.3]	0.341 [‡]
Platelets, x10⁹/L		279.5 (109.5)	243 (148.2)	282 (106.9)	0.518 [#]
Inflammation					
CRP, mg/L		61.5 [11.8, 157.5]	71 [29, 185.5]	60 [10, 156]	0.528 [‡]
Coagulation					
D-Dimers, mg/L FEU	<i>n (n missing)</i>	81 (31) 1264 [601, 2605]	5 (2) 1156 [1105, 1485]	76 (29) 1315 [573, 2651.5]	0.961 [‡]
PT, seconds		12 [11, 13.2]	13 [11.4, 14.5]	12 [11, 13.2]	0.434 [‡]
APTT, seconds	<i>n (n missing)</i>	111 (1) 27 [25, 31]	7 (0) 31 [27.1, 35.5]	104 (1) 26.9 [25, 30]	0.120 [‡]
Electrolytes					
Creatinine, µmol/L		69.5 [53.5, 107]	157 [112, 211.5]	67 [52, 104]	0.014 [‡]
Cardiac biomarkers					
NT-proBNP, ng/L	<i>n (n missing)</i>	100 (12) 458 [198.5, 1689.5]	7 (0) 4806 [2571.5, 17121]	93 (12) 429 [197, 1369]	0.006 [‡]
Abnormal NT-proBNP^A	<i>n (n missing)</i>	100 (12) 63 (63%)	7 (0) 6 (85.7%)	93 (12) 57 (61.3%)	0.255 [†]
hsTn I, ng/L	<i>n (n missing)</i>	64 (48) 12 [4.8, 42]	5 (2) 56 [38, 102]	59 (46) 11 [4, 37]	0.082 [‡]
hsTn T, ng/L	<i>n (n missing)</i>	46 (66) 16.5 [10, 28.5]	2 (5) 39 [34, 44]	44 (61) 16 [10, 26.2]	0.094 [‡]
Abnormal troponin^B	<i>n (n missing)</i>	110 (2) 51 (46.4%)	7 (0) 6 (85.7%)	103 (2) 45 (43.7%)	0.048 [†]
Clinical Parameters					
HR, bpm		79 (19.9)	99.1 (17.3)	77.7 (19.5)	0.016 [#]
Rhythm	Sinus	107 (95.5%)	7 (100%)	100 (95.2%)	>0.99 [†]
	AF/Flutter	5 (4.5%)	0 (0%)	5 (4.8%)	
Mean BP, mmHg	<i>n (n missing)</i>	109 (3) 80.9 (13.4)	7 (0) 74.1 (9.6)	102 (3) 81.3 (13.5)	0.100 [#]
CVP, cmH₂O	<i>n (n missing)</i>	74 (38) 7 [4, 12]	4 (3) 13.5 [10.2, 16.8]	70 (35) 7 [4, 11.8]	0.187 [‡]
Drug Administration					
Vasopressors		40 (35.7%)	4 (57.1%)	36 (34.3%)	0.246 [†]
Inotropes		1 (0.9%)	0 (0%)	1 (1%)	>0.99 [†]
Anticoagulation	Prophylactic	93 (83%)	3 (42.9%)	90 (85.7%)	0.018 [†]
	Therapeutic	17 (15.2%)	4 (57.1%)	13 (12.4%)	
	None	2 (1.8%)	0 (0%)	0 (0%)	
Paralysis		52 (46.4%)	3 (42.9%)	49 (46.7%)	>0.99 [†]
Ventilation					
FiO₂		0.6 [0.4, 0.7]	0.6 [0.5, 0.7]	0.6 [0.4, 0.7]	0.659 [‡]

Requirement for prone ventilation in previous 24 hours		44 (39.3%)	4 (57.1%)	40 (38.1%)	0.468 [†]
Plateau pressure, cmH₂O		58 (54)	5 (2)	53 (52)	
		24 [22, 27]	27 [27, 29]	24 [22, 27]	0.048 [‡]
PAP, cmH₂O	<i>n (n missing)</i>	58 (54)	5 (2)	53 (52)	
		25 [20, 30]	29 [27, 30.5]	25 [20, 29]	0.171 [‡]
Tidal volume, ml/kg (PBW)	<i>n (n missing)</i>	108 (4)	7 (0)	101 (4)	
		7.2 (2.1)	7.1 (3.3)	7.2 (2)	0.978 [#]
P/F ratio		17 [13.6, 21.3]	15.6 [12.5, 17.5]	17.5 [13.7, 21.5]	0.361 [‡]
PEEP, cmH₂O	<i>n (n missing)</i>	111 (1)	7 (0)	104 (1)	
		9.8 (3.6)	8.7 (3)	9.9 (3.6)	0.351 [#]
Resp rate (/minute)		24.3 (5.3)	25.3 (6.3)	24.2 (5.2)	0.676 [#]
Driving pressure, cmH₂O	<i>n (n missing)</i>	58 (54)	5 (2)	53 (52)	
		14.7 (7.1)	19.4 (5.1)	14.2 (7.1)	0.086 [#]
Dynamic compliance, ml/cmH₂O	<i>n (n missing)</i>	58 (54)	5 (2)	53 (52)	
		29.8 [20, 40]	18.8 [17, 20]	32.1 [21.1, 40.6]	0.031 [‡]
Murray lung injury score	<i>n (n missing)</i>	100 (12)	6 (1)	94 (11)	
		2.8 [2.3, 3]	2.9 [2.6, 3.2]	2.8 [2.3, 3]	0.491 [‡]

Data are presented as mean (SD), median [IQR] or n (%). Data are complete unless indicated by *n (n missing)*. P-values provided are for comparisons between RVD vs no RVD. # = Student's T-test. † = Fisher's Exact test. ‡ = Wilcoxon Mann-Whitney test. Missing data indicated by *n (n missing)*.

A, NT-proBNP ≥ 300 ng/L

B, hsTnT ≥ 15 ng/L or hsTnI ≥ 34 ng/L for males; ≥ 16 ng/L for females

RVD = Right Ventricular Dysfunction, RRT = Renal Replacement Therapy, BE = Base Excess, CRP = C-Reactive Protein, PT = Prothrombin Time, APTT = Activated Partial Thromboplastin Time, NT-proBNP = N-terminal pro B-type Natriuretic Peptide, hsTn = High Sensitivity Troponin, HR = Heart Rate, BP = Blood Pressure, CVP = Central Venous Pressure, FiO₂ = Fraction of Inspired Oxygen, PAP = Peak Airway Pressure, PBW = Predicted Body Weight, PEEP = Positive End Expiratory Pressure.

Table 6. Logistic regression predicting 30-day mortality adjusting for remaining variables in table

	OR (95% CI)	p-value
Abnormal NT-proBNP^A	4.77 (1.22, 21.32)	0.029
Abnormal Troponin^B	16.54 (4.98, 67.12)	<0.001
Age, in years (per 5-year increase)	1.62 (1.16, 2.39)	0.008
Female Gender	1.14 (0.33, 4.02)	0.834
Non-white ethnicity	1.74 (0.21, 13.91)	0.599
APACHE II score on admission to ICU (per 5-score increase)	1.08 (0.66, 1.80)	0.751
Time from intubation to date of echo, in days (per 1-day increase)	1.10 (0.91, 1.34)	0.341

A, NT-proBNP ≥ 300 ng/L

B, HSTnT ≥ 15 ng/L or HSTnI ≥ 34 ng/L for males; ≥ 16 ng/L for females

NT-proBNP = N-terminal pro B-type Natriuretic Peptide, APACHE = Acute Physiology And Chronic Health Evaluation

FIGURE LEGENDS

Figure 1. Patient recruitment

Figure 2. Proportion of patients with Right Ventricular Dysfunction

Figure 3. NT-proBNP levels in those with and without Right Ventricular Dysfunction (RV dilatation and septal flattening). NT-proBNP = N-terminal pro b-type natriuretic peptide

1. Szekely Y, Lichter Y, Taieb P, Banai A, Hochstadt A, Merdler I, Oz AG, Rothschild E, Baruch G, Peri Y, Arbel Y, Topilsky Y (2020) Spectrum of Cardiac Manifestations in COVID-19. *Circulation* 142: 342-353. <https://doi.org/10.1161/CIRCULATIONAHA.120.047971>
2. Michard F, Vieillard-Baron A (2021) Critically ill patients with COVID-19: are they hemodynamically unstable and do we know why? *Intensive Care Medicine* 47: 254-255. <https://link.springer.com/article/10.1007%2Fs00134-020-06238-5>
3. Argulian E, Sud K, Vogel B, Bohra C, Garg VP, Talebi S, Lerakis S, Narula J (2020) Right Ventricular Dilation in Hospitalized Patients with COVID-19 Infection. *JACC: Cardiovascular Imaging* 13: 2459-2461. <https://doi.org/10.1016/j.jcmg.2020.05.010>
4. Li Y, Li H, Zhu S, Xie Y, Wang B, He L, Zhang D, Zhang Y, Yuan H, Wu C, Sun W, Zhang Y, Li M, Cui L, Cai Y, Wang J, Yang Y, Lv Q, Zhang L, Xie M (2020) Prognostic Value of Right Ventricular Longitudinal Strain in Patients with COVID-19. *JACC: Cardiovascular Imaging* 13: 2287-2299. <https://doi.org/10.1016/j.jcmg.2020.04.014>
5. D'Alto M, Marra AM, Severino S, Salzano A, Romeo E, De Rosa R, Stagnaro FM, Pagnano G, Verde R, Murino P, Farro A, Ciccarelli G, Vargas M, Fiorentino G, Servillo G, Gentile I, Corcione A, Cittadini A, Naeije R, Golino P (2020) Right ventricular-arterial uncoupling independently predicts survival in COVID-19 ARDS. *Critical Care* 24: 670. <https://doi.org/10.1186/s13054-020-03385-5>
6. Kim J, Volodarskiy A, Sultana R, Pollie MP, Yum B, Nambiar L, Tafreshi R, Mitlak HW, RoyChoudhury A, Horn EM, Hriljac I, Narula N, Kim S, Ndhlovu L, Goyal P, Safford MM, Shaw L, Devereux RB, Weinsaft JW (2020) Prognostic Utility of Right Ventricular Remodeling Over Conventional Risk Stratification in Patients With COVID-19. *Journal of the American College of Cardiology* 76: 1965-1977. <https://doi.org/10.1016/j.jacc.2020.08.066>
7. Mahmoud-Elsayed HM, Moody WE, Bradlow WM, Khan-Kheil AM, Senior J, Hudsmith LE, Steeds RP (2020) Echocardiographic Findings in Patients With COVID-19 Pneumonia. *Canadian Journal of Cardiology* 36: 1203-1207. <https://doi.org/10.1016/j.cjca.2020.05.030>
8. Moody WE, Mahmoud-Elsayed HM, Senior J, Gul U, Khan-Kheil AM, Horne S, Banerjee A, Bradlow WM, Huggett R, Hothi SS, Shahid M, Steeds RP (2021) Impact of Right Ventricular Dysfunction on Mortality in Patients Hospitalized With COVID-19, According to Race. *CJC Open* 3: 91-100. <https://doi.org/10.1016/j.cjco.2020.09.016>
9. Pagnesi M, Baldetti L, Beneduce A, Calvo F, Gramegna M, Pazzanese V, Ingallina G, Napolano A, Finazzi R, Ruggeri A, Ajello S, Melisurgo G, Camici PG, Scarpellini P, Tresoldi M, Landoni G, Ciceri F, Scandroglio AM, Agricola E, Cappelletti AM (2020) Pulmonary hypertension and right ventricular involvement in hospitalised patients with COVID-19. *Heart* 106: 1324-1331. <http://dx.doi.org/10.1136/heartjnl-2020-317355>
10. Rath D, Petersen-Urbe Á, Avdiu A, Witzel K, Jaeger P, Zdanyte M, Heinzmann D, Tavlaki E, Müller K, Gawaz MP (2020) Impaired cardiac function is associated with mortality in patients with acute COVID-19 infection. *Clinical Research in Cardiology* 109: 1491-1499. <https://dx.doi.org/10.1007%2Fs00392-020-01683-0>
11. Park JF, Banerjee S, Umar S (2020) In the eye of the storm: the right ventricle in COVID-19. *Pulmonary Circulation*. July 2020. <https://doi.org/10.1177%2F2045894020936660>

12. Boissier F, Katsahian S, Razazi K, Thille AW, Roche-Campo F, Leon R, Vivier E, Brochard L, Vieillard-Baron A, Brun-Buisson C, Mekontso Dessap A (2013) Prevalence and prognosis of cor pulmonale during protective ventilation for acute respiratory distress syndrome. *Intensive Care Med* 39: 1725-1733. <https://doi.org/10.1007/s00134-013-2941-9>
13. Mekontso Dessap A, Boissier F, Charron C, Begot E, Repesse X, Legras A, Brun-Buisson C, Vignon P, Vieillard-Baron A (2016) Acute cor pulmonale during protective ventilation for acute respiratory distress syndrome: prevalence, predictors, and clinical impact. *Intensive Care Med* 42: 862-870. <https://doi.org/10.1007/s00134-015-4141-2>
14. Willder JM, McCall P, Messow C-M, Gillies M, Berry C, Shelley B (2021) Study protocol for COVID-RV: a multicentre prospective observational cohort study of right ventricular dysfunction in ventilated patients with COVID-19. *BMJ Open* 11: e042098. <http://dx.doi.org/10.1136/bmjopen-2020-042098>
15. Intensive Care Society (2021) Focused Ultrasound for Intensive Care. https://www.ics.ac.uk/Society/Society/Learning/FUSIC/Modules/FUSIC_Heart.aspx. Accessed 17th Feb 2021.
16. Heinze G, Schemper M (2002) A solution to the problem of separation in logistic regression. *Stat Med* 21: 2409-2419. <https://doi.org/10.1002/sim.1047>
17. Murray JF, Matthay MA, Luce JM, Flick MR (1988) An Expanded Definition of the Adult Respiratory Distress Syndrome. *American Review of Respiratory Disease* 138: 720-723. <https://doi.org/10.1164/ajrccm/138.3.720>
18. Lahm T, Douglas IS, Archer SL, Bogaard HJ, Chesler NC, Haddad F, Hemnes AR, Kawut SM, Kline JA, Kolb TM, Mathai SC, Mercier O, Michelakis ED, Naeije R, Tudor RM, Ventetuolo CE, Vieillard-Baron A, Voelkel NF, Vonk-Noordegraaf A, Hassoun PM (2018) Assessment of Right Ventricular Function in the Research Setting: Knowledge Gaps and Pathways Forward. An Official American Thoracic Society Research Statement. *Am J Respir Crit Care Med* 198: e15-e43. <https://doi.org/10.1164/rccm.201806-1160st>
19. Rudski LG, Lai WW, Afilalo J, Hua L, Handschumacher MD, Chandrasekaran K, Solomon SD, Louie EK, Schiller NB (2010) Guidelines for the Echocardiographic Assessment of the Right Heart in Adults: A Report from the American Society of Echocardiography Endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. *Journal of the American Society of Echocardiography* 23: 685-713. <https://doi.org/10.1016/j.echo.2010.05.010>
20. Pavlicek M, Wahl A, Rutz T, de Marchi SF, Hille R, Wustmann K, Steck H, Eigenmann C, Schwerzmann M, Seiler C (2011) Right ventricular systolic function assessment: rank of echocardiographic methods vs. cardiac magnetic resonance imaging. *European Journal of Echocardiography* 12: 871-880. <https://doi.org/10.1093/ejechocard/jer138>
21. McCall P, Willder JM, McErlane J, Shelley B (2021) A Call for Pragmatic Bedside Assessment of Right Ventricular (RV) Function in Coronavirus Disease 2019 (COVID-19). *Journal of Cardiothoracic and Vascular Anesthesia*. <https://doi.org/10.1053/j.jvca.2021.03.017>

22. Jardin F, Dubourg O, Bourdarias JP (1997) Echocardiographic pattern of acute cor pulmonale. Chest 111. <https://doi.org/10.1378/chest.111.1.209>
23. Creel-Bulos C, Hockstein M, Amin N, Melhem S, Truong A, Sharifpour M (2020) Acute Cor Pulmonale in Critically Ill Patients with Covid-19. New England Journal of Medicine 382: e70. <https://doi.org/10.1056/nejmc2010459>
24. Zochios V, Parhar K, Tunnicliffe W, Roscoe A, Gao F, (2017) The Right Ventricle in ARDS. CHEST 152: 181-193. <https://doi.org/10.1016/j.chest.2017.02.019>
25. Scottish Intensive Care Audit Group (2021) Scottish Intensive Care Society Audit Group report on COVID-19. https://beta.isdscotland.org/media/9117/2021-06-02_sicsag_report.pdf. Accessed 1st July 2021.
26. Intensive Care National Audit and Research Centre (2021) ICNARC report on COVID-19 in critical care: England, Wales and Northern Ireland 6 July 2021. <https://www.icnarc.org/our-audit/audits/cmp/reports>. Accessed 7th July 2021.
27. RECOVERY Collaborative Group (2020) Dexamethasone in Hospitalized Patients with Covid-19. New England Journal of Medicine 384: 693-704. <https://doi.org/10.1056/nejmoa2021436>
28. Docherty AB, Mulholland RH, Lone NI et al. (2021) Changes in in-hospital mortality in the first wave of COVID-19: a multicentre prospective observational cohort study using the WHO Clinical Characterisation Protocol UK. The Lancet Respiratory Medicine 7: 773-785. [https://doi.org/10.1016/S2213-2600\(21\)00175-2](https://doi.org/10.1016/S2213-2600(21)00175-2)
29. Jenner WJ, Kanji R, Mirsadraee S, Gue YX, Price S, Prasad S, Gorog DA, (2021) Thrombotic complications in 2928 patients with COVID-19 treated in intensive care: a systematic review. Journal of Thrombosis and Thrombolysis 51: 595-607. <https://dx.doi.org/10.1007%2Fs11239-021-02394-7>
30. Vieillard-Baron A, Schmitt JM, Augarde R, (2001) Acute cor pulmonale in acute respiratory distress syndrome submitted to protective ventilation: incidence, clinical implications, and prognosis. Crit Care Med 29. <https://doi.org/10.1097/00003246-200108000-00009>
31. Goldhaber SZ, Visani L, De Rosa M, (1999) Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 353: 1386-1389. [https://doi.org/10.1016/s0140-6736\(98\)07534-5](https://doi.org/10.1016/s0140-6736(98)07534-5)
32. Mueller C, Giannitsis E, Jaffe AS, Huber K, Mair J, Cullen L, Hammarsten O, Mills NL, Möckel M, Krychtiuk K, Thygesen K, Lindahl B, Association EGoBiCotACC, (2021) Cardiovascular biomarkers in patients with COVID-19. European Heart Journal Acute Cardiovascular Care 10: 310-319. <https://doi.org/10.1093/ehjacc/zuab009>
33. Parohan M, Yaghoubi S, Seraji A, (2020) Cardiac injury is associated with severe outcome and death in patients with Coronavirus disease 2019 (COVID-19) infection: A systematic review and meta-analysis of observational studies. European Heart Journal: Acute Cardiovascular Care 9: 665-677. <https://doi.org/10.1177%2F2048872620937165>

34. Jayasimhan D, Foster S, Chang CL, Hancox RJ, (2021) Cardiac biomarkers in acute respiratory distress syndrome: a systematic review and meta-analysis. *Journal of Intensive Care* 9: 36. <https://doi.org/10.1186/s40560-021-00548-6>
35. Middeldorp S, Coppens M, van Haaps TF, Foppen M, Vlaar AP, Müller MCA, Bouman CCS, Beenen LFM, Kootte RS, Heijmans J, Smits LP, Bonta PI, van Es N, (2020) Incidence of venous thromboembolism in hospitalized patients with COVID-19. *J Thromb Haemost* 18: 1995-2002. <https://doi.org/10.1111/jth.14888>